Clinical Trial Update: Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients [Phase 4]

View source ↗

Summary

Phase 4 trial assessing the safety and efficacy of pimecrolimus cream 1% in mild-to-moderate head and neck atopic dermatitis patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Pimecrolimus Cream 1% (pimecrolimus)

Snippet

Sponsor: Novartis | Conditions: Atopic Dermatitis | Phase 4 | Status: COMPLETED